Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
27 10 2020
Historique:
received: 04 06 2020
accepted: 30 09 2020
entrez: 28 10 2020
pubmed: 29 10 2020
medline: 20 11 2020
Statut: epublish

Résumé

The molecular characterisation of medulloblastoma, the most common paediatric brain tumour, is crucial for the correct management and treatment of this heterogenous disease. However, insufficient tissue sample, the presence of tumour heterogeneity, or disseminated disease can challenge its diagnosis and monitoring. Here, we report that the cerebrospinal fluid (CSF) circulating tumour DNA (ctDNA) recapitulates the genomic alterations of the tumour and facilitates subgrouping and risk stratification, providing valuable information about diagnosis and prognosis. CSF ctDNA also characterises the intra-tumour genomic heterogeneity identifying small subclones. ctDNA is abundant in the CSF but barely present in plasma and longitudinal analysis of CSF ctDNA allows the study of minimal residual disease, genomic evolution and the characterisation of tumours at recurrence. Ultimately, CSF ctDNA analysis could facilitate the clinical management of medulloblastoma patients and help the design of tailored therapeutic strategies, increasing treatment efficacy while reducing excessive treatment to prevent long-term secondary effects.

Identifiants

pubmed: 33110059
doi: 10.1038/s41467-020-19175-0
pii: 10.1038/s41467-020-19175-0
pmc: PMC7591522
doi:

Substances chimiques

Biomarkers, Tumor 0
Circulating Tumor DNA 0
DNA, Neoplasm 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5376

Références

Rep Pract Oncol Radiother. 2016 Jan-Feb;21(1):84-9
pubmed: 26900364
Cancer Cell. 2017 Jun 12;31(6):737-754.e6
pubmed: 28609654
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Lancet Oncol. 2017 Jul;18(7):958-971
pubmed: 28545823
Curr Top Dev Biol. 2011;94:235-82
pubmed: 21295689
Cancer Cell. 2014 Mar 17;25(3):393-405
pubmed: 24651015
Radiology. 1969 Dec;93(6):1351-9
pubmed: 4983156
Neuro Oncol. 2017 Oct 19;19(11):1542-1552
pubmed: 28605510
Ann Oncol. 2019 Feb 1;30(2):211-218
pubmed: 30576421
Acta Neuropathol. 2018 Jun;135(6):939-953
pubmed: 29644394
Acta Neuropathol. 2012 Apr;123(4):465-72
pubmed: 22134537
Cancer Cell. 2015 Jan 12;27(1):72-84
pubmed: 25533335
Ann Oncol. 2019 Oct 1;30(10):1580-1590
pubmed: 31373349
Lancet Oncol. 2018 Jun;19(6):785-798
pubmed: 29753700
Acta Neuropathol Commun. 2017 Apr 17;5(1):28
pubmed: 28416018
Nature. 2015 Oct 22;526(7574):519-24
pubmed: 26200345
Clin Cancer Res. 2018 Jun 15;24(12):2812-2819
pubmed: 29615461
Haematologica. 2020 Feb 20;:
pubmed: 32079701
N Engl J Med. 2009 Sep 17;361(12):1173-8
pubmed: 19726761
Nat Commun. 2015 Nov 10;6:8839
pubmed: 26554728
Acta Neuropathol. 2016 Jun;131(6):821-31
pubmed: 27040285
EMBO Mol Med. 2018 Dec;10(12):
pubmed: 30401727
J Neurosurg Pediatr. 2018 Feb;21(2):145-152
pubmed: 29219788
J Neurosurg. 2001 Nov;95(5):791-7
pubmed: 11702869
Cancer Biol Ther. 2016 Oct 2;17(10):1010-1016
pubmed: 27682250
J Clin Oncol. 2014 Feb 20;32(6):579-86
pubmed: 24449238
Nature. 2017 Jul 19;547(7663):311-317
pubmed: 28726821
Clin Cancer Res. 2018 Dec 1;24(23):5850-5859
pubmed: 30322880
PLoS One. 2012;7(12):e51422
pubmed: 23284693
Nat Rev Cancer. 2020 Jan;20(1):42-56
pubmed: 31819232
Mol Clin Oncol. 2018 Oct;9(4):415-418
pubmed: 30233795
Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):9704-9
pubmed: 26195750
Genome Med. 2018 Mar 28;10(1):25
pubmed: 29592813
Nature. 2018 Mar 15;555(7696):321-327
pubmed: 29489754
Nature. 2019 Jan;565(7741):654-658
pubmed: 30675060
Lancet Oncol. 2013 Nov;14(12):1200-7
pubmed: 24140199
Nat Genet. 2017 May;49(5):780-788
pubmed: 28394352
Nucleic Acids Res. 2014 Jan;42(Database issue):D980-5
pubmed: 24234437
J Pediatr Hematol Oncol. 2016 May;38(4):269-73
pubmed: 26907655
Acta Neuropathol Commun. 2019 Jul 30;7(1):123
pubmed: 31362788
Sci Transl Med. 2012 May 30;4(136):136ra68
pubmed: 22649089
Pediatr Neurosurg. 1994;20(4):240-7
pubmed: 8043462
J Clin Oncol. 2016 Jul 10;34(20):2404-15
pubmed: 27161972
Prog Neurobiol. 2006 Feb-Apr;78(3-5):272-303
pubmed: 16759785
Am J Med. 2012 Jul;125(7):636-41
pubmed: 22560808

Auteurs

Laura Escudero (L)

Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.

Anna Llort (A)

Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.

Alexandra Arias (A)

Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.

Ander Diaz-Navarro (A)

Dpto. de Bioquímica y Biología Molecular, IUOPA-Universidad de Oviedo, 33006, Oviedo, Spain.
CIBERONC, Barcelona, Spain.

Francisco Martínez-Ricarte (F)

Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.
Universitat Autònoma de Barcelona (UAB), 08193, Cerdanyola del Vallès, Spain.

Carlota Rubio-Perez (C)

Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.

Regina Mayor (R)

Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.

Ginevra Caratù (G)

Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.

Elena Martínez-Sáez (E)

Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.

Élida Vázquez-Méndez (É)

Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.

Iván Lesende-Rodríguez (I)

Universidade de A Coruña (UDC), 15006, A Coruña, Spain.

Raquel Hladun (R)

Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.

Luis Gros (L)

Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.

Santiago Ramón Y Cajal (S)

Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.

Maria A Poca (MA)

Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.
Universitat Autònoma de Barcelona (UAB), 08193, Cerdanyola del Vallès, Spain.

Xose S Puente (XS)

Dpto. de Bioquímica y Biología Molecular, IUOPA-Universidad de Oviedo, 33006, Oviedo, Spain.
CIBERONC, Barcelona, Spain.

Juan Sahuquillo (J)

Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.
Universitat Autònoma de Barcelona (UAB), 08193, Cerdanyola del Vallès, Spain.

Soledad Gallego (S)

Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron University Hospital, 08035, Barcelona, Spain.
Universitat Autònoma de Barcelona (UAB), 08193, Cerdanyola del Vallès, Spain.

Joan Seoane (J)

Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain. jseoane@vhio.net.
CIBERONC, Barcelona, Spain. jseoane@vhio.net.
Universitat Autònoma de Barcelona (UAB), 08193, Cerdanyola del Vallès, Spain. jseoane@vhio.net.
Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010, Barcelona, Spain. jseoane@vhio.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH